NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) General Counsel Alicia C. Olivo sold 5,175 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
NeoGenomics Stock Performance
NeoGenomics stock opened at $15.36 on Wednesday. The firm's fifty day moving average price is $14.67 and its 200-day moving average price is $14.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The stock has a market cap of $1.97 billion, a P/E ratio of -24.61 and a beta of 1.19. NeoGenomics, Inc. has a fifty-two week low of $12.77 and a fifty-two week high of $21.22.
NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million for the quarter, compared to analysts' expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.06) EPS. On average, equities research analysts expect that NeoGenomics, Inc. will post -0.17 earnings per share for the current fiscal year.
Institutional Trading of NeoGenomics
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
From Darwin | Ad
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential.
Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
👉 Click here to access your FREE report now!
Several institutional investors and hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC grew its holdings in shares of NeoGenomics by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 25,683 shares of the medical research company's stock valued at $404,000 after purchasing an additional 1,765 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of NeoGenomics by 9.8% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 39,920 shares of the medical research company's stock valued at $695,000 after purchasing an additional 3,550 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of NeoGenomics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 14,211,019 shares of the medical research company's stock valued at $223,397,000 after purchasing an additional 41,354 shares during the last quarter. Edgestream Partners L.P. bought a new position in shares of NeoGenomics during the 1st quarter valued at $1,894,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of NeoGenomics by 4.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 142,809 shares of the medical research company's stock valued at $2,245,000 after purchasing an additional 6,148 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, November 6th. Stephens restated an "overweight" rating and set a $19.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Benchmark reiterated a "buy" rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, September 24th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $20.25.
Read Our Latest Report on NEO
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
